Global /Italy /Healthcare /Biotechnology /UBM
chevron_leftBack
Helyx Industries S.p.A. logo

Helyx Industries S.p.A.

UBM
MIL: UBM Delayed
0.6280EUR -0.3%
0.7292 USD
As of 18 June 2026, Helyx Industries S.p.A. has a market cap of $19.06M USD, ranking #37464 globally and #306 in Italy. It ranks #3363 in the Healthcare sector, and #661 in the Biotechnology industry.
Global Rank
37464
Country Rank
306
Sector Rank
3363
Industry Rank
661
Key Stats
Market Cap
$19.06MUSD
16.41M EUR
Enterprise Value
$18.89MUSD
16.27M EUR
Revenue (TTM)
$2.24MUSD
1.93M EUR
EBITDA (TTM)
-$1.82MUSD
-1.57M EUR
Net Income (TTM)
-$5.08MUSD
-4.38M EUR
EBITDA Margin
-81%
Profit Margin
-227%
PS Ratio
8.5
PB Ratio
0.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Nicola Basile open_in_new
Employees
18
Founded
2015
Website
helyx.bio open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.3% 1.3% -11% -19% -40% -16%

News

Loading...

Markets

Exchange Ticker Price
Borsa Italiana
MIC: XMIL
PRIMARY
UBM
Ulisse Biomed SpA
ISIN: IT0005451213
Shares Out.:
25.51M1
TV:
SA:
YF:
GF:
BA:
UBM
MS:
0.6280 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Helyx Industries S.p.A.

Helyx Industries S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV. In addition, the company’s platforms also comprise NanoHybrid, a platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. The company was formerly known as Ulisse Biomed S.p.A. and change its name to Helyx Industries S.p.A. in December 2025. Helyx Industries S.p.A. was founded in 2015 and is based in Udine, Italy.

Similar Companies

Industry: Biotechnology (Italy)
Name
Market Cap diff.
PE
$23.66M
20.37M EUR
24%
15.2
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
957K%
23.9
GILD
$159.92B
839K%
19.0
ARGX
$48.06B
41.39B EUR
252K%
39.9
$44.7B
68.19T KRW
234K%
35.5
LONN
$42.51B
33.71B CHF
223K%
37.2
CSL
$42.44B
60.27B AUD
223K%
29.3
chevron_leftBack